Ultimately, better characterization of the downstream effects of ccf-mtDNA and sTNFR1 on chronic inflammation in AD and frailty can help identify novel drug targets that can reduce the high mortality and morbidity of these syndromes. The gene discussed is PITX1; the disease is Alzheimer disease.